BioInformatics Secures $21M Series B Funding to Acquire Kalorama Information, Files S-1 Registration Statement

Recently, VCBeat (WeChat Official Account: vcbeat) learned from foreign media reports that BioInformatics, a leading U.S. research consulting firm serving the life sciences industry, has recently completed a $21 million Series B financing round. The investors in this round include BroadOak Capital, Pablo Capital, and Research Corporation Technologies. Additionally, as part of this financing arrangement, Mark Anderson, Partner at Pablo Capital, along with Bill Snider and Tim Johnson, existing board members from BroadOak Capital, will join the Board of Directors of BioInformatics.

Bioinformatics, established in 1994, is a leading research consulting firm serving the life sciences and diagnostics industries, primarily providing critical market intelligence for the life sciences, analytical instrumentation, and clinical diagnostics markets. Its areas of expertise include assessing market size and attractiveness, optimizing product portfolios and pricing, validating corporate acquisitions, measuring customer brand loyalty, and evaluating brand strength and positioning. The company’s multidisciplinary team comprises industry veterans, market research specialists, consultants, and survey statisticians.

Image from Unsplash official website

Since its inception, BioInformatics has been dedicated to solving problems for companies in the life sciences, analytical instrumentation, and clinical diagnostics sectors, providing not only data but also actionable intelligence to its clients. By leveraging an expert network comprising more than 50,000 life scientists, the company has supported over 500 companies across the life sciences, clinical diagnostics, radiology, and dental markets. This support helps them launch products on BioInformatics’ digital platform or enhance business decision-making through its market intelligence data and publications.

Upon completion of the financing, BioInformatics intends to allocate the funds toward its planned acquisition of Kalorama Information, a leading publisher in the medical research market, while reserving additional capital to finance future strategic acquisitions by BioInformatics. Originally established as the joint publishing division of Find/SVP with a focus on the U.S. healthcare market, Kalorama was acquired by MarketResearch in 1998. Following a shift in its business focus and restructuring of its analytical team, Kalorama expanded its coverage to a global scale. For over two decades, Kalorama has been a leading publisher of market research in the healthcare sector, primarily covering areas such as in vitro diagnostics, biotechnology, healthcare services, medical devices, and pharmaceuticals.

Regarding this acquisition, Craig Overpeck, CEO of BioInformatics, stated: “Kalorama Information is a premier source of high-quality market research reports for corporate decision-makers in the clinical diagnostics and life sciences sectors. This acquisition further solidifies our leadership position in the life sciences, diagnostics, and imaging markets, while also providing us with opportunities in the broader healthcare market, including medical devices, pharmaceuticals, and biotechnology.”

As part of the Science and Medicine Group, BioInformatics stated that following the acquisition of Kalorama Information, the data and resources provided by Kalorama will be integrated with BioInformatics’ existing asset capabilities. All companies and assets under BioInformatics will be jointly managed and consolidated within the Science and Medicine Group. In March this year, BioInformatics also acquired IMV Publishing, a company primarily engaged in market research for the medical imaging and clinical diagnostics equipment markets, as well as online publishing.

BroadOak Capital is a private venture capital firm and M&A advisory company. Since its establishment in 2006, BroadOak has successfully completed more than 50 life sciences-related M&A transactions.

RCT, established in 1987, is a technology investment and management firm that provides early-stage funding to promising biopharmaceutical companies and technologies, and drives technological development through venture capital, partnerships, and special licensing programs. To support its portfolio companies, RCT has assembled an investment team with expertise in life sciences, medical devices, therapeutic research and development, and financial management.

Science and Medicine Group is a consortium of industry-leading brands that provides premier research and consulting services to the life sciences, diagnostics, and analytical instrumentation sectors, addressing their specific business challenges. The group engages the market through various innovative solutions, helping companies in analytical instrumentation, life sciences, imaging, and clinical diagnostics develop strategies and products to capture market share.